Helix Therapeutics
New Haven
About Helix Therapeutics
Helix Therapeutics, Inc. develops deoxyribonucleic acid (DNA) based therapeutics. It develops novel sequence-specific gene-targeting reagents for the treatment of HIV/AIDS and common genetic diseases, such as sickle cell anemia, thalassemia, and cystic fibrosis.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $3.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2010)
- Website: helixtherapeutics.com
- Phone: 203-772-2888
Industries & Categories
Biotechnology, Genetics, Therapeutics
Canonical: https://fsome.com/organization/helix-therapeutics-3240043 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.